Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.34 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.34 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6600771 | 0.88 | SMN1; SMN2 (0.45) | HRH3SMN1; SMN2SIGMAR1MAPTCARM1 | |
| SCHEMBL13899773 | 0.86 | PAOX (0.42) | SIGMAR1MAPT | |
| SCHEMBL13880146 | 0.86 | SMN1; SMN2 (0.48) | HRH3SMN1; SMN2SIGMAR1CYP1A2MAPT | |
| SCHEMBL6039721 | 0.83 | ALDH1A1 (0.44) | SMN1; SMN2SIGMAR1MAPT | |
| SCHEMBL7649942 | 0.76 | HRH3 (0.52) | HRH3SMN1; SMN2SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL3861129 | 0.76 | HRH3 (0.43) | HRH3SMN1; SMN2CYP1A2MAPK1MAPT | |
| SCHEMBL7649376 | 0.74 | HRH3 (0.56) | HRH3SMN1; SMN2SIGMAR1CYP1A2MAPK1 | |
| SCHEMBL12553864 | 0.74 | SMN1; SMN2 (0.54) | SMN1; SMN2CARM1PRMT6PRMT8 | |
| SCHEMBL17526227 | 0.74 | SIGMAR1 (0.55) | HRH3SIGMAR1 | |
| SCHEMBL17526223 | 0.74 | SIGMAR1 (0.55) | HRH3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7504399-B2 | Piperazine enamines as antiviral agents | BRISTOL-MEYERS SQUIBB COMPANY (US) | 2009-03-17 | — | — | US | disclosed |
| US-20070287712-A1 | Piperazine Enamines as Antiviral Agents | BRISTOL-MYERS SQUIBB COMPANY | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287712-A1 | Piperazine Enamines as Antiviral Agents | INMT, ITPA, IDO1 | HRH3 1610/4885SMN1; SMN2 3295/4885SIGMAR1 779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.